Search Results - "HARAF, D"

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer by Seiwert, T.Y., Foster, C.C., Blair, E.A., Karrison, T.G., Agrawal, N., Melotek, J.M., Portugal, L., Brisson, R.J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M.W., Villaflor, V.M., Ginat, D.T., Haraf, D.J., Vokes, E.E.

“…Patients with HPV+ oropharyngeal squamous cell carcinoma were assigned to dose and volume de-escalated radiotherapy (RT) or chemoradiotherapy (CRT) based on…”
Get full text

Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience by Brockstein, B., Haraf, D. J., Rademaker, A. W., Kies, M. S., Stenson, K. M., Rosen, F., Mittal, B. B., Pelzer, H., Fung, B. B., Witt, M.-E., Wenig, B., Portugal, L., Weichselbaum, R. W., Vokes, E. E.

“…Background: Locoregionally advanced, stage IV head and neck cancer has traditionally carried a poor prognosis. We sought to assess changes in patterns of…”
Get full text

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer by Villaflor, V.M., Melotek, J.M., Karrison, T.G., Brisson, R.J., Blair, E.A., Portugal, L., De Souza, J.A., Ginat, D.T., Stenson, K.M., Langerman, A., Kocherginsky, M., Spiotto, M.T., Hannigan, N., Seiwert, T.Y., Cohen, E.E.W., Vokes, E.E., Haraf, D.J.

“…Efforts to reduce the late toxicity associated with chemoradiation (CRT) for locally advanced head and neck squamous cell cancer (LA-HNSCC) have focused on…”
Get full text

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer by Seiwert, T.Y., Foster, C.C., Blair, E.A., Karrison, T.G., Agrawal, N., Melotek, J.M., Portugal, L., Brisson, R.J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M.W., Villaflor, V.M., Ginat, D.T., Haraf, D.J., Vokes, E.E.

Get full text

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers by Salama, J.K., Haraf, D.J., Stenson, K.M., Blair, E.A., Witt, M.E., Williams, R., Kunnavakkam, R., Cohen, E.E.W., Seiwert, T., Vokes, E.E.

“…We conducted a randomized phase II study to evaluate the impact of adding bevacizumab (B) to 5-fluorouracil (5-FU), hydroxyurea (HU), and radiotherapy (FHX)…”
Get full text

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels by Salama, J.K., Stenson, K.M., Kistner, E.O., Mittal, B.B., Argiris, A., Witt, M.E., Rosen, F., Brockstein, B.E., Cohen, E.E.W., Haraf, D.J., Vokes, E.E.

“…We hypothesized induction chemotherapy (IndCT) would improve distant control (DC) without compromising locoregional control (LRC) for locoregionally advanced…”
Get full text

507 Evaluation of patients with progressive metastatic head and neck cancer treated with PD-1 inhibition with Pembrolizumab and radiation therapy: Assessment of local and systemic effects by Das, L.C, Haraf, D, Brisson, R, McHugh, M, Cheng, J, Heath, K, Villaflor, V, Vokes, E.E, Weichselbaum, R.R, Seiwert, T.Y

Get full text

Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma by Knab, B.R., Salama, J.K., Solanki, A., Stenson, K.M., Cohen, E.E., Witt, M.E., Haraf, D.J., Vokes, E.E.

“…Randomized trials established chemoradiotherapy as standard treatment for advanced laryngeal cancer. Patients with large-volume T4 disease (LVT4) were excluded…”
Get full text

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades by Das, L.C., Karrison, T.G., Witt, M.E., Muller, C., Stenson, K., Blair, E.A., Cohen, E.E.W., Seiwert, T.Y., Haraf, D.J., Vokes, E.E.

“…Human papillomavirus (HPV) has emerged as a causative agent and positive prognostic factor for oropharyngeal (OP) head and neck squamous cell cancer (HNSCC)…”
Get full text

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation by Seiwert, T.Y., Darga, T., Haraf, D., Blair, E.A., Stenson, K., Cohen, E.E.W., Salama, J.K., Villaflor, V., Witt, M.E., Lingen, M.W., Weichselbaum, R.R., Vokes, E.E.

“…AdGV.EGR.TNF.11D (TNFerade™ Biologic) is a replication-deficient adenoviral vector expressing human tumor necrosis factor alpha (TNF-α) under the control of…”
Get full text

Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer by Shumway, D, Corbin, K, Salgia, R, Hoffman, P, Villaflor, V, Malik, R.M, Haraf, D.J, Vigneswaren, W.T, Shaikh, A.Y, Connell, P.P, Ferguson, M.K, Salama, J.K

“…Abstract Introduction Treatment of technically operable, medically fit locoregionally advanced non-small cell lung cancer (NSCLC) patients is a controversial…”
Get full text

Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma by Golden, D.W, Rudra, S, Witt, M.E, Nwizu, T, Cohen, E.E.W, Blair, E, Stenson, K.M, Vokes, E.E, Haraf, D.J

“…Summary Purpose Current standard therapy for nasopharyngeal carcinoma (NPC) is concurrent chemoradiation based on randomized data. However, limited randomized…”
Get full text

Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer by VOKES, E. E, KIES, M. S, HSIEH, Y.-C, MITTAL, B. B, WEICHSELBAUM, R. R, HARAF, D. J, STENSON, K, LIST, M, HUMERICKHOUSE, R, DOLAN, M. E, PELZER, H, SULZEN, L, WITT, M. E

“…To achieve locoregional control of head and neck cancer, survival, and organ preservation using intensive concomitant chemoradiotherapy. This study was a phase…”
Get full text

Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer by Oh, J. L., Vokes, E. E., Kies, M. S., Mittal, B. B., Witt, M. E., Weichselbaum, R. R., Haraf, D. J.

“…Background: Since 1990, we have treated patients with advanced nasopharyngeal cancer with induction chemotherapy and concomitant chemoradiotherapy. We herein…”
Get full text

Concomitant Infusional Paclitaxel and Fluorouracil, Oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer by KIES, Merrill S, HARAF, Daniel J, RADEMAKER, Alfred, WEICHSELBAUM, Ralph, VOKES, Everett E, ROSEN, Fred, STENSON, Kerstin, LIST, Marcy, BROCKSTEIN, Bruce, CHUNG, Theodore, MITTAL, Bharat B, PELZER, Harold, PORTUGAL, Louis

“…To improve local disease control and survival with organ preservation, we conducted a phase II multi-institutional trial with a concomitant taxane-based…”
Get full text

Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck by Villaflor, V.M., Haraf, D., Salama, J.K., Kocherginsky, M., Langerman, A., Gomez-Abuin, G., Beniwal, P., Blair, E.A., Stenson, K.M., Portugal, L., Seiwert, T., Williams, R.D., Dekker, A.J., Witt, M.E., Vokes, E.E., Cohen, E.E.W.

“…Concurrent chemoreirradiation therapy (CRRT) offers a therapeutic option for patients with locoregionally recurrent squamous cell carcinoma of the head and…”
Get full text

Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary by Argiris, A., Smith, S. M., Stenson, K., Mittal, B. B., Pelzer, H. J., Kies, M. S., Haraf, D. J., Vokes, E. E.

“…Background: Our aim was to explore the use of concurrent chemoradiotherapy in the management of patients with squamous cell carcinoma of the head and neck from…”
Get full text

Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: A potentially curable disease by Haraf, D. J., Weichselbaum, R. R., Vokes, E. E.

“…Purpose: The purpose of this study was to review the outcome following concomitant chemoradiation therapy in previously irradiated patients with locally or…”
Get full text

Phase I study of docetaxel with concomitant thoracic radiation therapy by Mauer, A M, Masters, G A, Haraf, D J, Hoffman, P C, Watson, S M, Golomb, H M, Vokes, E E

“…The taxanes have demonstrated activity as radiation sensitizers in preclinical studies. This study was designed to determine the maximum-tolerated dose (MTD),…”
Get more information

Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival by HARAF, D. J, NODZENSKI, E, BRACHMAN, D, MICK, R, MONTAG, A, GRAVES, E, VOKES, E. E, WEICHSELBAUM, R. R

“…Recent studies have shown that p53 mutations are frequently found in cancer of the head and neck, whereas others have indicated that human papilloma virus…”
Get full text